Blog

Posted onbyDouglas M. Sheeley, Sc.D., NIH Common Fund

Vesicle

New Tool Predicts Response to Immunotherapy in Lung Cancer Patients

With just a blood sample from a patient, a promising technology has the potential to accurately diagnose non-small cell lung cancer (NSCLC), the most-common form of the disease, more than 90 percent of the time. The same technology can even predict from the same blood sample whether a patient will...

Read More . . .


This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) 9000 Rockville Pike Bethesda MD 20892 301-496-4000 / TTY 301-402-9612 GovDelivery logo